Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis

Table 5 Summary of meta-analysis outcomes for Japanese type 2 diabetes patients <65 and ≥65 years of age

Outcome	Effect estimate	95 % Confidence limits		p value	Effect estimate	95 % Confidence limits		p value
		Lower	Upper			Lower	Upper
		<65 years of age				≥65 years of age
Change in HbA1c (%)	−1.00	−1.29	−0.72	<0.0001	−1.24	−1.55	−0.92	<0.0001
Change in weight (kg)	−0.15	−1.07	0.76	0.74	−0.58	−1.39	0.22	0.16
Change in FPG (mg/dL)	−11.2	−23.3	0.9	0.07	−14.8	−29.9	0.3	0.06
Change in PPG: meal test (mg/dL)	−138.1	−177.0	−99.2	<0.0001	−166.5	−228.3	−104.6	<0.0001

	Odds ratio	95 % Confidence limits		p value	Odds Ratio	95 % Confidence limits		p value
		Lower	Upper			Lower	Upper
		<65 years of age				≥65 years of age
Symptomatic hypoglycemia	2.3	1.0	5.6	0.06	5.1	1.3	19.7	0.0197
Severe hypoglycemia	0.0	0.0	0.0	–	0.0	0.0	0.0	–
Endpoint HbA1c <7 %	13.1	3.4	50.7	0.0002	23.2	4.1	131.9	0.0004
Endpoint HbA1c <7 % and no weight gain	8.4	2.1	33.8	0.0026	16.7	2.9	95.7	0.0015
Endpoint HbA1c <7 % and no symptomatic hypoglycemia	14.0	2.6	76.8	0.0023	12.3	2.1	70.7	0.0049
Endpoint HbA1c <7 % and no weight gain and no symptomatic hypoglycemia	7.8	1.3	45.6	0.0221	10.1	1.7	58.3	0.0100